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Aim: Prescription of inhaled corticosteroids to children with asthma is recommended at half
the nominal dose of adults in order to reduce the risk of systemic side effects. However, there
is a lack of pharmacokinetic trials supporting such dose reduction regimens. Therefore, we
aimed to compare the systemic exposure to the active ingredients of a fixed dose combination
of beclometasone-dipropionate (BDP) and formoterol after dry powder inhaler (DPI) adminis-
tration in children, adolescents and adults.
Methods: The pharmacokinetic profiles of formoterol and beclometasone-17-monopropionate
(B17MP; active metabolite of BDP) were evaluated over 8 h from two independent studies
comprising children (6e11yrs, n Z 27), adolescents (12e17 yrs, n Z 28) and adults (18
yrs, n Z 30) receiving a single, fixed dose of BDP/formoterol (children: 200 mg/24 mg, adoles-
cents and adults: 400 mg/24 mg) via DPI.lasma drug concentrationetime curve; BDP, beclometasone-dipropionate; B17MP, beclometasone-17-
ea; Cmax, maximum plasma concentration; DPI, dry powder inhaler; FEV1, forced expiratory volume in
oid; PK, pharmacokinetic; pMDI, pressurized metered dose inhaler; t1/2, half-life; tmax, time to
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support guideline recommendaResults: The systemic exposure (AUC) for children versus adults was almost doubled for formo-
terol and similar for B17MP despite the halved BDP dose administered in children. In adoles-
cents the AUC for formoterol and B17MP were approximately one third higher than in adults
for both compounds. Upon normalization for the BDP/formoterol dose in the three populations
the AUC and peak concentration (Cmax) correlated inversely with age and body surface area of
the patients (r  0.53; p < 0.0001).
Conclusion: The systemic exposure to the active ingredients of BDP/formoterol administered
as DPI correlates inversely with age and body size suggesting that dry powder dosage regimens
should be adjusted for age and body size to avoid high systemic drug levels in children.
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systemic exposure from a fixed dose of beclometasone-dipropionate/formoterol DPI
d body surface area resulting in increased blood levels in younger patients. The findings
tions of a reduced dosage regimen of dry powder formulations in children in order toIntroduction Therefore, we compared the pharmacokinetic profiles afteravoid systemic side effects such as growth retardation.Asthma guidelines recommend prescription of inhaled
corticosteroid (ICS) to children adjusted according to age
and body size. Thus, ICS dosage to children is recommended
in half the nominal dose of that recommended in adults
[1e3]. The rationale behind dose reduction in children is
based on a concern for systemic side effects such as
impaired growth rate [4] and reduced adult height [5].
However, the influence of age and body size on the pro-
portion of an inhaled drug dose that reaches the systemic
circulation, i.e. the systemic exposure, is poorly
understood.
In two previous studies comparing the systemic exposure
to a fixed nominal dose of budesonide pressurized metered
dose inhaler (pMDI) inhaled from a spacer (Nebuchamber)
in children and adults [6] and a fixed nominal dose of
beclometasone-dipropionate (BDP)/formoterol combina-
tion pMDI inhaled from the AeroChamber Plus spacer de-
vice in children, adolescents and adults [7] we found
comparable levels of ICS and long acting b2-agonists (LABA)
in the bloodstream independently of age and body size.
This suggests that the current praxis of dose reduction in
children to avoid high systemic exposure may be unnec-
essary when prescribing ICS pMDI with a spacer.
The purpose of the current work was to investigate if the
systemic exposure to ICS is also independent of age and
body size when inhaled from a dry powder inhaler (DPI).a single dose administration of BDP/formoterol combina-
tion DPI in children, adolescents and adults with asthma.Methods
Patients
Study data was collected from two independent clinical
trials, one performed on children (6e11 yrs) [Clinical-
Trials.gov Identifier: NCT01468272]. Identifier:
NCT01468272] and one on adolescents (12e17 yrs) and
adults (18 yrs) [ClinicalTrials.gov Identifier: 108
NCT01191424]. Identifier: NCT01191424]. Children, ado-
lescents and adults with a documented clinical history of
asthma diagnosed according to the GINA guidelines [8] and
under regular treatment with ICS or ICS/LABA or using
short-acting inhaled b2-agonist as reliever therapy to con-
trol asthma symptoms were considered for inclusion in the
study. Eligible patients were those able to properly use a
DPI and with a pre-bronchodilator Forced Expiratory Vol-
ume in one second (FEV1) >70% of predicted values [9].
Main exclusion criteria were exacerbation of asthma
symptoms or lower respiratory tract infection within the
previous 4 weeks and past or present cardiovascular, renal
or liver disease. The clinical trials were carried out in
accordance with the Declaration of Helsinki (1996), the ICH
1110 B.L. Chawes et al.Harmonized Tripartite Guideline for Good Clinical Practice
(GCP) and with applicable regulatory requirements. Pro-
tocols were approved by Independent Ethics Committee.
Written informed consent was obtained from the parents/
guardians at the screening visit.
Study design
Each age group population was treated according to an
open label, randomized, single dose, two-way crossover
design in which asthmatic patients were dosed with the
fixed combination BDP/formoterol DPI (NEXThaler, Chiesi
Farmaceutici, Parma, Italy) in one treatment period and
with the equivalent nominal dose of BDP DPI and formoterol
DPI given separately in another treatment period. A wash-
out period of at least 7 days separated each drug admin-
istration. In the present study the pharmacokinetic (PK)
profiles of formoterol and beclometasone-17-
monopropionate (B17MP, active metabolite of BDP) ob-
tained after treatment with the fixed BDP/formoterol
combination DPI were compared between the different age
group populations.
A screening visit including medical history, physical ex-
amination, and lung function assessment was performed
within 30 days before the first drug administration. At this
screening visit and prior to the study drug administrations,
patients practiced the inhalations with placebo DPI until
the investigator judged the technique to be optimal. The
patients were instructed to hold their breath for as long as
possible (>5 s) following each inhalation and to wait about
30 s before taking the next inhalation.
Prior to each study drug administration, intake of short
acting b2-agonists, LABA and BDP had to be avoided for at
least 4, 24 and 48 h, respectively. The study drug was a dry
powder fixed combination of BDP 100 mg and formoterol
6 mg per actuation (BDP/formoterol 100/6 DPI) for adults
and adolescents and BDP/formoterol 50/6 DPI for children.
Patients were dosed with 4 inhalations of BDP/formoterol
DPI for a total dose of 400 mg/24 mg in adults and adoles-
cents and 200 mg/24 mg in children. The dosage corre-
sponded to the total allowed daily dose in order to properly
assess the plasma profile of the analytes also during the
elimination phase taking into account that especially for-
moterol plasma levels are very low even at the maximum
daily dosage of 24 mg.
Evaluable patients in this study were all those receiving
BDP/formoterol DPI excluding subjects without any valid PK
measurement over 8 h post-dose or with major protocol
deviations significantly affecting the pharmacokinetics such
as incorrect inhalation, change in patient condition (e.g.
worsening of asthma, cold), failure in delivery of the de-
vice, use of non-permitted medications. Study patients
were not excluded on the basis of statistical analysis or for
PK reasons.
Pharmacokinetic assessments
Patients attended the clinics in the morning of the admin-
istration day after having fasted overnight and remained
fasted until 2 h post-dosing. They remained seated as much
as possible, avoided strenuous activities, and remainedunder constant surveillance of the nursing staff. No alcohol
or xanthine containing beverages or foods (tea, chocolate,
cola, etc.) or grapefruits were allowed from 48 h before
each drug administration until 24 h after administration. No
food or drink, except water, was allowed for 2 h after drug
administration.
Prior to study drug administration, an intravenous can-
nula was inserted into a cubital vein anesthetized with
Lidocain gel (EMLA) for collection of blood samples.
The administration of the study drug was made in a
dedicated room well separated from the blood sampling
station and the on-site laboratory to avoid any risk of
contamination.
Blood samples were collected pre-dose and at 0.25, 0.5,
1, 2, 4, 6, 8 h post-dose. Blood samples for B17MP and
formoterol determination in plasma were collected into
vacuum tubes containing EDTA and lithium heparin,
respectively. All samples were immediately chilled on ice
bath and plasma preparation was done within 15 min after
blood collection. The plasma was separated in a refriger-
ated centrifuge at þ4 C and at 2500 rpm for 15 min and
subsequently transferred into prelabelled polypropylene
tubes. For stabilizing the formoterol compound, the poly-
propylene tubes were pre-filled with 50 mL of citric acid and
centrifuged before use in order to ensure that the citric
acid was at the bottom of each tube. Samples for B17MP
and formoterol analysis were stored below 20 C and
65 C, respectively, before shipment on cold dry ice to the
laboratory (SGS Life Sciences Services, Belgium). The PK
assays were performed using validated liquid
chromatography-mass spectrometry (LC-MS/MS) methods
with lower limit of quantification of 2 pg/ml for formoterol
and 50 pg/ml for B17MP [10].
The following PK parameters were calculated from the
individual plasma drug concentration vs. time profiles:
maximum plasma concentration (Cmax), time to maximum
plasma concentration (tmax), area under the plasma con-
centrationetime curve observed from 0 to 8 h post dose and
to infinity (AUC0et, AUC0eN, respectively) and half-life (t1/
2) calculated as 0.693/lz, where lz is the first order ter-
minal rate constant.Data analyses
PK study calculations and statistical comparisons of PK data
were performed according to a noncompartmental kinetic
model using Phoenix WinNonlin version 6.2.1 (Pharsight
Corporation, USA). AUC was calculated using the linear
trapezoidal rule. We tested age dependency of AUC and
AUC normalized for the body surface area (BSA) as
AUC  BSA where BSA was calculated according to the
Mosteller formula [11]. All PK variables were log trans-
formed and analyzed with an analysis of variance (ANOVA)
model. The 90% confidence intervals (CIs) for the ratio of
the geometric means were derived from the model.
Equivalence was demonstrated if the 90% CI range was
within the 0.8e1.25 acceptance region [12]. Statistical
comparisons of demography data and correlation assess-
ments were performed by means of one-way ANOVA fol-
lowed by post-hoc Dunnett’s test for multiple comparisons
and Spearman’s non-parametric test, respectively, using
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USA). Differences and correlations were considered signif-
icant at p <0.05.
Results
Study population
Twenty-seven patients were enrolled in the children trial.
One child was withdrawn after treatment leaving 26 chil-
dren evaluable for this study (6 aged 6e8 yrs and 20 aged
9e11 yrs). 18 were males (69%) and 8 were females (31%)
with an overall mean age of 9.3 yrs (range 6e11). One out
of the 26 evaluable patients was excluded from the PK
analysis of B17MP due to a missing plasma concentration 8 h
post-dose.
Twenty-eight patients were enrolled in the adolescent
trial and all of them were evaluable for this study. 15 were
males (54%) and 13 were females (46%) with an overall
mean age of 13.9 yrs (range 12e17).
Thirty patients were enrolled in the adult trial and all of
them were evaluable for this study. 17 were males (57%)
and 13 females (43%) with an overall mean age of 35.1 yrs
(range 19e59). Two out of the 30 evaluable patients were
excluded from the PK analysis of B17MP due to missing
plasma concentrations 8 h post-dose.
In the three age group populations BSA increased
significantly from children to adolescents and from ado-
lescents to adults (p < 0.001) (Online Fig. E1). The mean
BSA was 1.15 m2 (range 0.78e1.46) for children, 1.56 m2
(range 1.23e1.86) for adolescents and 1.90 m2 (range
1.49e2.19) for adults.
The study population demography data are outlined in
Table 1.
Pharmacokinetics
The overall summary of PK parameters and the mean
plasma concentrationetime profiles over the 8 h sampling
period are represented in Table 2 and Figs. 1 and 2. The
systemic exposures were higher in adolescents as compared
to adults for both B17MP and formoterol. The point esti-
mates (PE) and 90% CI of the geometric means ratio ado-
lescents/adults for AUC0et was 1.42 (90% CI, 1.28e1.57) for
B17MP and 1.20 (90% CI, 1.08e1.35) for formoterol (Table
3). Similarly to the systemic exposure, Cmax was higher in
adolescents as compared to adults for both B17MP (PE,Table 1 Study group demography.
Children (N Z 26)
Age (years) 9.3 (1.5; 6e11)
Weight (kg) 34 (8; 19e52)
Height (cm) 139 (11; 116e157)
BMI (kg/m2) 17.5 (2.3; 14.1e24.0)
BSA (m2) 1.15 (0.17; 0.78e1.46)
FEV1 (L) 1.81 (0.42; 1.01e2.69)
FEV1 %pred (%) 91 (13; 72e111)
Results are presented as the mean (SD; range). BMI: body mass inde
formula; FEV1: pre-bronchodilator forced expiratory volume in 1 s; FE1.68; 90% CI, 1.50e1.89) and formoterol (PE, 1.27; 90% CI,
1.11e1.44) (Table 3). Upon normalization for BSA of each
individual patient, the systemic exposure was equivalent
for adolescent and adults. In fact, the 90% CI of the geo-
metric means ratio adolescents/adults for the variables
AUC0et  BSA and AUC0einf  BSA were completely within
the bioequivalence reference intervals of 0.8e1.25 [12]
with the only exception for AUC0et of B17M with the
upper 90% CI of 1.27 being slightly above the upper refer-
ence level (Table 3).
Children in comparison to adults were treated with a
halved dose of BDP (200 mg vs. 400 mg) but with the same
dose of formoterol (24 mg). Despite a halved BDP dose in
children, the systemic exposures in children and adults
were comparable for B17MP, while it was higher in children
for formoterol (Table 3). The PE of the geometric means
ratios children/adults for AUC0et was 0.90 (90% CI,
0.81e1.00) for B17MP, and 1.85 (90% CI, 1.64e2.07) for
formoterol (Table 3). Similarly, the PE for Cmax was 1.23
(90% CI, 1.09e1.39) for B17MP and 1.86 (90% CI, 1.62e2.13)
for formoterol (Table 3). Upon normalization for BSA, the
systemic exposure of children in comparison to adults was
halved for B17MP (according with the halved dose of BDP)
and equivalent for formoterol: the 90%CI of AUC  BSA was
within the range 0.40e0.625 for B17MP and within the
bioequivalence range of 0.80e1.25 for formoterol (Table
3).
The terminal half-lives (t1/2) for both B17MP and for-
moterol were similar among the three age group pop-
ulations. Mean (SD) t1/2 for children, adolescents, and
adults were: 2.6  0.7 h, 2.6  0.6 h and 3.5  0.7 h for
B17MP and 3.6  0.7 h, 4.0  0.9 h and 4.7  1.7 h for
formoterol, respectively.
Upon normalization for the BDP/formoterol dose in the
three age group populations (normalization of the BDP
component in children to 400 mg), the systemic exposure
and peak concentration to B17MP and formoterol expressed
as AUC0et and Cmax correlated inversely with the BSA
(r  0.71; p < 0.0001) and age (r  0.53; p < 0.0001) of
the patients (Figs. 3 and 4).
Discussion
Main finding
The systemic exposure to the active metabolite of BDP
(B17MP) and formoterol after dry powder inhalationAdolescents (N Z 28) Adults (N Z 30)
13.9 (1.7; 12e17) 35.1 (10.4; 19e59)
54 (9; 38e71) 75 (12; 50e97)
162 (10; 142e181) 174 (9; 151e192)
20.4 (1.9; 18.6e26.5) 25.0 (2.9; 19.9e30.7)
1.56 (0.18; 1.23e1.86) 1.90 (0.19; 1.49e2.19)
3.01 (0.65; 1.91e4.52) 3.56 (0.87; 2.25e5.46)
105 (15; 77e142) 97 (14; 77e118)
x; BSA: body surface area calculated according to the Mosteller
V1 % pred: FEV1 % of predicted normal value.
Table 2 Beclometasone 17-monopropionate (B17MP) and formoterol pharmacokinetic parameters in children, adolescents
and adults.
AUC0et
(pg*h/mL)
Mean (SD)
AUC0einf
(pg*h/mL)
Mean (SD)
Cmax (pg/mL)
Mean (SD)
tmax (h)
Median (range)
t1/2 (h)
Mean (SD)
AUC0et  BSA
(pg*h*m2/mL)
Mean (SD)
AUC0einf  BSA
(pg*h*m2/mL)
Mean (SD)
B17MP
Children
(N Z 25)
2160.7 (504.7) 2496.2 (621.9) 740.0 (224.3) 0.50 (0.25e1.00) 2.6 (0.7) 2426.1 (567.9) 2815.3 (759.9)
Adolescents
(N Z 28)
3373.2 (629.5) 3876.42 (685.24) 997.8 (246.8) 0.50 (0.25e2.00) 2.6 (0.6) 5222.5 (945.6) 6026.4 (1182.7)
Adults
(N Z 28)
2394.7 (555.0) 3019.0 (736.0) 590.5 (142.4) 0.75 (0.25e2.00) 3.5 (0.7) 4513.5 (886.9) 5697.4 (1245.7)
Formoterol
Children
(N Z 26)
162.5 (45.4) 208.4 (59.3) 74.7 (20.2) 0.25 (0.25e0.28) 3.6 (0.7) 181.1 (37.7) 232.7 (53.6)
Adolescents
(N Z 28)
106.0. (28.4) 142.7 (41.2) 52.3 (18.3) 0.25 (0.25e1.05) 4.0 (0.9) 162.8 (37.6) 219.6 (58.0)
Adults
(N Z 30)
86.7 (18.0) 121.0 (24.7) 39.9 (9.0) 0.25 (0.25e0.27) 4.7 (1.7) 164.1 (33.6) 230.0 (50.4)
AUC Z Area under the plasma drug concentrationetime curve; Cmax Z maximum plasma concentration; tmax Z time to maximum
plasma concentration; t1/2 Z half-life; BSA Z body surface area calculated according to the Mosteller formula.
1112 B.L. Chawes et al.correlates inversely with age and body size. Thus,
increasing blood levels of the active components were
observed with decreasing age and BSA. These findings sug-
gest that anti-asthmatic dry powder dosage regimens
should be adjusted for age and body size to avoid high
systemic drug levels in children.
Interpretation
In this study the systemic exposure to the active ingredients
of BDP/formoterol after DPI administration in children as
compared to adults was almost doubled for formoterol and
similar for B17MP despite the halved BDP dose administered
in children. Although more modest, the systemic exposureFigure 1 Beclometasone-17-monopropionate (B17MP)
plasma profiles. Average plasma concentrations (95% confi-
dence intervals) after four inhalations of beclometasone-
dipropionate/formoterol DPI (50 mg/6 mg in children and
100 mg/6 mg in adolescents and adults) for a total single
beclometasone-dipropionate dose of 200 mg in children and
400 mg in adolescents and adults.after BDP/formoterol DPI administration was also higher in
adolescents as compared to adults. After normalization of
the systemic exposure for BSA, the same nominal dose of
formoterol administered with DPI in children, adolescents
and adults led to equivalent exposures in the three pop-
ulations, while a halved dose of BDP in children led to
halved exposure of B17MP in comparison to adolescents and
adults.
The PK properties of inhaled drugs assuming mono-
compartmental distribution in the body after absorption to
the systemic circulation depends on the volume of distri-
bution of the drug in the body (reasonably proportional to
the BSA), the total amount of drug absorbed systemically,
the total systemic exposure (AUC) and the elimination
constant (lz) calculated as 0.693/half-life of the drug [13]:Figure 2 Formoterol plasma profiles. Average plasma con-
centrations (95% confidence intervals) after four inhalations of
beclometasone-dipropionate/formoterol DPI (50 mg/6 mg in
children and 100 mg/6 mg in adolescents and adults) for a total
single formoterol dose of 24 mg in each age group population.
Volumeofdistributionof thedrug inthebodycompartmentZAmountofdrugabsorbed intothebodycompartment=ðAUClzÞ
Table 3 Pharmacokinetic (PK) analysis of beclometasone 17-monopropionate (B17MP) and formoterol after administration of
beclometasone-dipropionate/formoterol DPI in children and adolescents vs. adults.
Test PK variable B17MP Formoterol
Point estimate 90% CI Point estimate 90% CI
Adolescents/adults AUC0et 1.42 1.28e1.57 1.20 1.08e1.35
AUC0einf 1.30 1.18e1.44 1.15 1.03e1.30
AUC0et  BSA 1.16 1.06e1.27 0.99 0.90e1.09
AUC0einf  BSA 1.06 0.96e1.18 0.95 0.85e1.05
Cmax 1.68 1.50e1.89 1.27 1.11e1.44
Children/adults AUC0et 0.90 0.81e1.00 1.85 1.64e2.07
AUC0einf 0.83 0.74e0.92 1.69 1.50e1.90
AUC0et  BSA 0.53 0.48e0.59 1.10 1.00e1.22
AUC0einf  BSA 0.49 0.44e0.54 1.01 0.91e1.13
Cmax 1.23 1.09e1.39 1.86 1.62e2.13
The point estimate is calculated as ratio of the geometric means for the different PK parameters between the age group populations.
AUC Z Area under the plasma drug concentrationetime curve; Cmax Z maximum plasma concentration; tmax Z time to maximum
plasma concentration; t1/2 Z half-life; BSA Z body surface area calculated according to the Mosteller formula.
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to the amount of drug absorbed into the body compart-
ment/lz. In the current study, BSA  AUC was equivalent in
the three age group populations for both B17MP and for-
moterol and the half-lives were similar. It follows that the
amount of drug absorbed to the bloodstream after admin-
istration of BDP/formoterol DPI is similar in the three ageFigure 3 Correlation between exposure and body surface area
(AUC) to beclometasone-17-monopropionate (B17MP) and formot
Correlations were considered significant at p <0.05 (Spearman’s no
was normalized to a beclometasone-dipropionate dose of 400 mg.group populations with the net effect of a higher systemic
exposure in younger patients with smaller BSA.
Contrasting the present findings previous similar in-
vestigations demonstrated that when using a pMDI with a
spacer the amount of drug reaching the systemic circulation
for the same nominal dose is lower in young patients
resulting in similar systemic exposure in children,. Correlation between the rate (Cmax) and extent of exposure
erol and the body surface area (BSA) of individual patients.
n-parametric test). In children the systemic exposure to B17MP
Figure 4 Correlation between exposure and age. Correlation between the rate (Cmax) and extent of exposure (AUC) to
beclometasone-17-monopropionate (B17MP) and formoterol and the body surface area (BSA) of individual patients. Correlations
were considered significant at p <0.05 (Spearman’s non-parametric test). In children the systemic exposure to B17MP was
normalized to a beclometasone-dipropionate dose of 400 mg.
1114 B.L. Chawes et al.adolescents and adults [6,7]. Although it is well established
that different inhaler devices may be used differently by
patients, these diverging observations may be attributed to
the different characteristics of the two ways of inhaling the
drugs. Indeed, when inhaling an aerosol using a pMDI plus
spacer the amount of drug reaching the lung is dependent
on the inhalation time and tidal volume of the subject due
to exponential emptying of the spacer [14]. As both inha-
lation time and tidal volume is lower in younger patients,
this leads to comparable exposures among the different age
groups. An additional explanation is that narrow upper
airway geometry in children may have a filtering effect and
subsequently lead to a decreased amount of aerosol
penetrating into the lower airways compared to adults. This
explanation is supported by an in vitro airway cast study
showing that a decreased mass of fine particle aerosol
passes through the cast of the upper airway of a child
compared with the cast of the upper airway of an adult
[15]. Differently, with the use of a breath actuated DPI
[16], the age dependent respiratory capacity of the subject
is less likely to influence the amount of drug reaching the
lung resulting in systemic concentrations inversely corre-
lated to the body size of patients. Regardless of the inha-
lation system, the upper airway dimensions of children may
have a filtering effect on aerosol/dry powder penetration
to the lungs.
For the paediatric pulmonologist treating childhood
asthma these findings support guideline recommendations
that ICS DPI dosage in the paediatric population should be
adjusted to approximately half the adult dose to rendersimilar systemic exposure. However, when prescribing ICS
pMDI with a spacer to young children safety concerns should
not prompt dose reduction as the systemic exposure in
children is age and body size independent. Particular
caution is warranted in the transition phase when the child
with persistent asthma grows older and is shifted from pMDI
plus spacer to a DPI to titrate the dose in order to achieve
sufficient asthma control and preclude the occurrence of
side effects [5,17,18].
Therefore it is important that dose recommendations
specifically take into account the delivery device, i.e.
advising dose adjustment when using DPI but not when
using pMDI and spacer.Strengths and limitations of the study
It is a limitation that this study assessed pharmacokinetics
only and the correlation between systemic exposure and
clinical safety profile is not fully established.
It is another limitation that data is pooled from two in-
dependent cross-over trials (one in children and one in
adolescents and adults) designed to investigate PK bio-
equivalence between the fixed combination of BDP/for-
moterol DPI vs. the separate application of BDP and
formoterol DPIs. Due to this and the limited amount of
study subjects, replication of the findings is necessary.
It is an advantage that the studies were conducted under
strictly standardized conditions according to the European
Medicines Agency’s “Guideline on the Investigation of
Age and body size vs. systemic exposure after DPI 1115Bioequivalence” [12] and with external monitoring ac-
cording to the ICH GCP guidelines. The storage, preparation
and administration of the study drug were consistent in the
two studies, which were performed by a small highly
trained team handling all procedures according to pre-
defined standard operating procedures. The blood samples
were processed identically in the studies and all samples
were analyzed in the same laboratory with the same
methods. Also, the study drug was administered in the
morning at approximately the same time in all the trials to
minimize any circadian variation in PK parameters [19]. The
minimum wash-out period of 7 days eliminated the risk of
carry-over effect taking into account 5 times the terminal
half-life [12].
Conclusion
The systemic exposure to the active ingredient of BDP
(B17MP) and formoterol after dry powder inhalation in
asthmatic children, adolescents and adults correlates
inversely with age and body size resulting in increased
blood levels in younger patients. This suggests that anti-
asthmatic dry powder dosage regimens for children should
be adjusted for age and body size to avoid high systemic
drug levels and subsequent risk of unwanted side effects.
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